SEC Contract Filing

Filing Date: 2022-03-08

Document Content:
<DOCUMENT>
<TYPE>EX-10.48
<SEQUENCE>4
<FILENAME>tmb-20211231xex10d48.htm
<DESCRIPTION>EX-10.48
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge 9.11.0.85--><!--Created on: 3/7/2022 11:47:17 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;">EXECUTION COPY</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.48</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-size:12pt;font-weight:bold;">COMMERCIAL PAYMENT PURCHASE AGREEMENT<br><br>dated as of October 6, 2021<br><br>between<br><br></b><b style="font-family:'Times New Roman Bold';font-size:11.5pt;font-weight:bold;text-transform:uppercase;">Affitech Research AS</b><b style="font-size:12pt;font-weight:bold;">, as Seller,<br><br>and<br><br>XOMA (US) LLC, as Purchaser</b></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">COMMERCIAL PAYMENT PURCHASE AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This <b style="font-weight:bold;">COMMERCIAL PAYMENT PURCHASE AGREEMENT</b> (this &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;), dated as of October 6, 2021 (the &#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;), is between <b style="font-weight:bold;">AFFITECH RESEARCH AS</b> (formerly known as <font style="text-transform:uppercase;">Affitech</font> AS), a Norwegian company with the organization number 976 567 900, with their office and place of business at Lillogata SM, 0484 Oslo, Norway (&#8220;<b style="font-weight:bold;">Seller</b>&#8221; or &#8220;<b style="font-weight:bold;">Assignor</b>&#8221;), and <b style="font-weight:bold;">XOMA (US) LLC</b>, a Delaware limited liability company with its principal place of business at 2200 Powell Street, Suite 310, Emeryville, California 94608 (&#8220;<b style="font-weight:bold;">Purchaser</b>&#8221; or &#8220;<b style="font-weight:bold;">Assignee</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">W I T N E S E T H:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Seller and its Affiliates (collectively, &#8220;<b style="font-weight:bold;">Affitech</b>&#8221;) on the one hand, and F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (&#8220;<b style="font-weight:bold;">Roche Basel</b>&#8221;) and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (&#8220;<b style="font-weight:bold;">Roche Little Falls</b>&#8221;; Roche Basel and Roche Little Falls together referred to as &#8220;<b style="font-weight:bold;">Roche</b>&#8221;) on the other hand, were parties to that certain Research and License Agreement effective as of May 4, 2007 (the &#8220;<b style="font-weight:bold;">Roche License Agreement</b>&#8221;), pursuant to which Affitech performed certain research and granted Roche certain rights and licenses;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, pursuant to that certain Asset Purchase Agreement, effective as of December 14, 2020, by and between Affitech and Roche (the &#8220;<b style="font-weight:bold;">Roche APA</b>&#8221;), the parties thereto terminated and superseded t